Lanzol

Lansoprazole, the active ingredient in Lanzol, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat acid‑related disorders such as gastro‑esophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Lanzol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Lansoprazole is indicated for several acid‑related conditions that involve excessive gastric acid secretion.

Gastro‑esophageal reflux disease: provides relief of heartburn and promotes healing of esophageal irritation. Peptic ulcer disease: facilitates healing of gastric and duodenal ulcers. Erosive esophagitis: restores mucosal integrity in the esophagus. Helicobacter pylori eradication: used as part of combination therapy to eliminate H. pylori infection.

Lansoprazole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache - Diarrhea - Nausea

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis or angioedema - Clostridioides difficile‑associated diarrhea - Low magnesium levels (hypomagnesemia) with prolonged therapy

Before prescribing Lanzol, clinicians should consider several safety aspects.

Assess renal function: adjust use in severe renal impairment. Evaluate CYP2C19 status: polymorphisms may affect drug exposure. Monitor long‑term therapy: increased risk of bone fracture and vitamin B12 deficiency. Avoid concomitant use with drugs that require acidic pH for absorption (e.g., ketoconazole). Use caution in hepatic impairment: dose may need adjustment. Store at room temperature: keep in original container, protect from moisture and light.

Lansoprazole can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Atazanavir: reduced absorption and therapeutic effect. - Clarithromycin: increased lansoprazole plasma concentrations. - Methotrexate: heightened toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: may raise serum digoxin levels. - Clopidogrel: potential reduction of antiplatelet activity.